NIH SBIR/STTR Equipment Budgeting: What Is Allowable

SBIR and STTR budgets carry the same 2 CFR Part 200 equipment rules as any other NIH grant — but the mechanism itself layers on constraints that a general NIH equipment guide does not cover: SBIR/STTR applications are always excluded from NIH’s modular budget format regardless of dollar amount, they run against a hard statutory funding ceiling per phase, and NIH review panels apply the standard scored criteria plus an SBIR/STTR-specific Commercialization Potential criterion that equipment-heavy Phase I budgets tend to trip. This guide covers what is actually allowable, how the equipment line interacts with the Phase I/II funding caps, and why reviewers push back on equipment purchases more in this mechanism than in an R01.

This is the SBIR/STTR-specific companion to CASRAI’s NIH Grant Equipment Purchases guide, which covers the general 2 CFR 200 equipment framework (definitions, budgeting, prior approval, procurement, documentation) that applies to any NIH award. Read that guide for the full mechanics; this one covers only what changes when the award is a Phase I or Phase II SBIR/STTR.

Equipment Is Allowable — If It’s Necessary to the Specific R&D Objectives

There is no SBIR/STTR-specific carve-out that makes equipment more or less allowable than on any other NIH grant. The governing standard is still 2 CFR 200.403: a cost must be necessary and reasonable for the performance of the award, allocable to it, consistently treated, and adequately documented. For equipment specifically, “necessary” means necessary to accomplish the technical objectives stated in your research plan — not desirable, not useful for the lab generally, and not infrastructure you’d want regardless of whether this specific award existed.

What differs in practice is how hard that standard gets applied. A Phase I SBIR/STTR award is explicitly a feasibility study — typically 6–12 months, testing scientific/technical merit and feasibility before any commitment to full development. A budget that reads as “buy the instrument, then figure out the science” inverts that logic, and NIH SBIR/STTR study sections notice. The core NIH scored review criteria (Significance, Investigators, Innovation, Approach, Environment) apply to SBIR/STTR applications the same as any other NIH grant, but SBIR/STTR review adds a sixth, mechanism-specific element: Commercialization Potential, evaluated separately (it doesn’t fold into the overall Impact score) but weighed in the funding decision. An equipment-heavy Approach section without a tight explanation of why that specific instrument is the only way to answer the Phase I feasibility question reads, to a reviewer, as a capitalization request wearing a research-plan disguise — a common source of Approach-criterion concern in this mechanism specifically.

2 CFR 200.1’s equipment definition itself is unchanged for SBIR/STTR: tangible personal property (including IT systems) with a useful life over one year and a per-unit acquisition cost at or above the lesser of your institution’s own capitalization threshold or $10,000 (raised from $5,000 in OMB’s April 2024 Uniform Guidance revision, effective for awards issued on or after October 1, 2024). The general-purpose vs. special-purpose equipment distinction also carries over unchanged — see the general equipment guide and CASRAI’s Capital Equipment and Equipment cost (grant) dictionary entries for the full definitions.

SBIR/STTR Applications Never Use the Modular Budget

NIH’s modular budget format — direct costs requested in $25,000 increments up to $250,000 per budget period, without a line-item categorical breakdown — is explicitly unavailable to SBIR/STTR applications regardless of the dollar amount requested. This exclusion applies alongside the exclusions for foreign organizations and for any request above the $250,000 threshold; SBIR/STTR sits in its own always-detailed-budget category. See CASRAI’s NIH Modular Budgets guide for the modular-format mechanics that SBIR/STTR applicants skip entirely.

The practical consequence: every SBIR/STTR budget, at every dollar level, uses NIH’s full categorical (non-modular) budget form. Equipment must be itemized as its own line, with each item individually described and its cost individually justified in the budget justification narrative — it cannot be folded into supplies or “other expenses” the way a smaller, informally-justified item sometimes gets treated on a modular award. There is no dollar floor below which an SBIR/STTR equipment purchase escapes itemization; a $2,000 line item gets the same individual-justification treatment as a $40,000 one, because the whole budget is already at the itemized level of detail. See CASRAI’s Budget Justification Narrative guide for what a defensible categorical justification actually needs to say.

How Equipment Interacts With the Phase I/II Funding Ceilings

SBIR and STTR awards operate under statutory guideline funding levels that agencies can exceed only with an SBA waiver. For the current award cycle, the guideline levels are up to $323,090 for Phase I and up to $2,153,927 for Phase II (both figures include any amendments/supplements). These are program-wide guideline ceilings set by SBA, not an NIH-specific number, and individual NIH institutes can set lower per-topic caps in a given funding opportunity — check the specific FOA before assuming the full guideline amount is available.

Equipment doesn’t get special ceiling treatment the way it does on the F&A side: capital expenditures are excluded from the Modified Total Direct Cost base under 2 CFR 200.439(b)(7), so a large instrument purchase doesn’t also inflate your indirect-cost recovery — but it is not excluded from the overall award ceiling itself. A $50,000 instrument in a $323,090 Phase I budget consumes roughly 15% of the entire award before a single hour of labor is costed. That arithmetic is a large part of why equipment-heavy Phase I requests draw scrutiny: at the Phase I scale, a substantial equipment line crowds out the personnel and materials budget that actually executes the feasibility work, in a way the same purchase wouldn’t at Phase II’s roughly 6.6x larger ceiling. If your feasibility study genuinely requires a piece of capital equipment, the budget justification needs to explain not just why the instrument is necessary, but why it’s necessary now, at Phase I scale, rather than deferred to Phase II once feasibility is established. See CASRAI’s SBIR Phase I vs. Phase II comparison for the full duration/award-size/eligibility differences between the two phases.

Prior Approval and Procurement: The Same 2 CFR 200 Rules, No Mechanism Exception

2 CFR 200.439 sets the prior-approval framework, and it applies to SBIR/STTR exactly as it does to any other NIH grant: general purpose equipment requires the federal awarding agency’s prior written approval as a direct cost regardless of dollar amount, while special purpose equipment (the kind most SBIR/STTR feasibility work actually needs) is allowable without prior approval below the $10,000 per-unit threshold and requires prior written approval at or above it. Procurement method requirements under 2 CFR 200 Subpart D (micro-purchase, small purchase/simplified acquisition with competitive quotes, sealed bids, competitive proposals, sole source) also apply unchanged. CASRAI’s Equipment and Capital Expenditures Prior Approval Under 2 CFR 200.439 guide covers this threshold and process mechanics in full — nothing about the SBIR/STTR mechanism changes it, so that guide is the right place for the procedural detail rather than repeating it here.

One mechanism-specific wrinkle worth flagging: not every SBIR/STTR award is a grant. NIH issues the large majority of its SBIR/STTR funding as grants (subject to 2 CFR Part 200 cost principles, which is what this guide and the general equipment guide both assume), but some solicitations — and some other agencies’ SBIR/STTR programs more heavily — are structured as contracts, which follow FAR Part 31 cost principles instead. The equipment allowability test looks similar under either framework (necessity to the specific work, reasonableness, consistent treatment) but the prior-approval and disposition mechanics differ. Confirm your award instrument before assuming 2 CFR 200 governs; see CASRAI’s SBIR Contracts: When the Award Is a Contract, Not a Grant guide if yours is contract-funded.

Buy, Lease, or Share? The Phase I Calculus Is Different From a Standard R01

Because Phase I is short (commonly 6–12 months) and its ceiling is comparatively small, the buy/lease/access decision carries more weight than it does on a multi-year R-series award where an instrument’s cost amortizes across years of use. A few practical patterns worth weighing before defaulting to a purchase line:

• Core facility access. If the specific capability exists at a shared university/institutional core facility (or, for a small business without academic affiliation, at a contract-research or fee-for-service lab), a per-use or per-sample fee is a supplies/services cost, not an equipment line — it avoids the prior-approval threshold, the procurement documentation burden, and the disposition question entirely. See CASRAI’s Core Facility Equipment Sharing Agreements guide.
• Leasing. A lease is generally a rental cost under the applicable cost principles rather than a capital acquisition, which sidesteps the $10,000 prior-approval trigger — though the lease-vs-buy comparison has its own allowability and reasonableness analysis. See CASRAI’s Lab Equipment & Supplies Procurement guide and Capital Equipment Financing for Labs guide for the mechanics.
• Deferring the purchase to Phase II. If the equipment genuinely isn’t required to answer the feasibility question — only to scale the work after feasibility is demonstrated — the stronger reviewer-facing argument is often to budget it into a Phase II request instead, where the larger ceiling absorbs it proportionally better and the commercialization case for owning the instrument is easier to make.

Sourcing note: for biomedical SBIR/STTR feasibility work that does call for owned diagnostic, monitoring, or imaging instrumentation, CASRAI’s sister medical-supply site LAC maintains a live Diagnostic, Monitoring & Imaging category page worth checking for current pricing and availability alongside your institution’s normal vendor comparison — useful as one more sourcing point among several, not a substitute for the competitive-quote documentation your procurement office requires.

End-of-Project Disposition Matters More on a Short Phase I

Because a Phase I period of performance is short, the question of what happens to equipment if the project doesn’t advance to Phase II arrives faster than it would on a longer award. The disposition rules themselves are the same as on any federal grant: at $10,000 per-unit acquisition cost or above, disposition instructions from the agency are required at project end (2 CFR 200.313); below that threshold, the awardee generally retains the equipment with no further federal obligation. Build the disposition question into your planning at the budgeting stage, not after a no-go decision on Phase II — particularly for equipment that’s genuinely dedicated to a single line of technical work and has limited use elsewhere in the business. CASRAI’s general equipment guide and its Prior Approval Under 2 CFR 200.439 guide (both linked above) cover the disposition mechanics in more depth.

FAQ

Is equipment an allowable cost on an NIH SBIR/STTR budget?

Yes, under the same 2 CFR 200.403 standard that governs any NIH award: the equipment must be necessary and reasonable to accomplish the specific research objectives in your technical proposal, allocable to the award, and adequately documented. There’s no SBIR/STTR-specific allowability exception in either direction — what changes is the scrutiny reviewers apply given Phase I’s feasibility scope and comparatively small ceiling.

Can I use NIH’s modular budget for an SBIR/STTR application?

No. SBIR/STTR applications are excluded from NIH’s modular budget format regardless of the dollar amount requested — every SBIR/STTR budget uses the full categorical (non-modular) form, with equipment itemized as its own justified line.

Does an equipment purchase count against the Phase I or Phase II funding ceiling?

Yes. Equipment is excluded from the Modified Total Direct Cost base for F&A/indirect-cost calculation purposes, but it is not excluded from the overall award total, which is what the statutory Phase I/Phase II guideline ceilings measure. A large equipment line consumes a proportionally bigger share of a Phase I budget than the same purchase would at Phase II’s larger ceiling.

Do I need NIH’s prior written approval to buy equipment on an SBIR/STTR grant?

The same 2 CFR 200.439 rule applies as on any NIH grant: general purpose equipment needs prior written approval regardless of cost, and special purpose equipment needs it only at or above the $10,000 per-unit acquisition-cost threshold. Nothing about the SBIR/STTR mechanism changes this threshold.

Why do SBIR/STTR reviewers push back on equipment-heavy Phase I budgets specifically?

Phase I is explicitly a short feasibility study, and NIH SBIR/STTR review adds a Commercialization Potential criterion on top of the standard Significance/Investigators/Innovation/Approach/Environment criteria. A budget dominated by a capital purchase, without a tight justification for why that specific item is necessary to answer the feasibility question at Phase I scale (rather than useful lab infrastructure generally), tends to read as weak on Approach and raises the question of whether the request is really about the R&D or about capitalizing the business.

Is every NIH SBIR/STTR award subject to 2 CFR 200 equipment rules?

Only if it’s issued as a grant, which is the case for most NIH SBIR/STTR funding. A smaller subset of SBIR/STTR awards, more common at some other agencies, are issued as contracts instead and follow FAR Part 31 cost principles rather than 2 CFR 200. Confirm your specific award instrument before assuming the grant rules apply.